StockData

Generate Biomedicines, Inc. (GENB) stock

GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$10.38+0.54 (+5.49%)

Close on Nov 18, 2026Market cap $1.33BP/E –Yield –

Generate Biomedicines net income

Net income is the profit left for shareholders after every expense, interest and tax.

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$87.66M–
Q2 FY2026Jun 30, 2026-$67.26M–
Q1 FY2026Mar 31, 2026-$61.45M–
Q3 FY2025Sep 30, 2025-$53.62M–
Q2 FY2025Jun 30, 2025-$52.43M–
Q1 FY2025Mar 31, 2025-$41.69M–

More Generate Biomedicines figures

See a number that looks wrong?